Metformin
Metformin Hydrochloride (Off-Label Longevity)
A first-line diabetes drug with 60+ years of clinical history, now emerging as the most evidence-backed pharmaceutical for anti-aging. The Bannister study showed metformin users outliving non-diabetic controls, and the TAME trial is the first FDA-approved trial targeting aging itself.
Key Research
Peer-Reviewed Evidence • 4 Citations
Can people with type 2 diabetes live longer than those without?
Bannister CA et al.•Diabetes Obes Metab•2014•PMID: 25041462
Key Finding: Metformin users lived 15% longer than matched non-diabetic controls (n=180,926, 503,384 person-years).
View on PubMedEffect of intensive blood-glucose control with metformin (UKPDS 34)
UKPDS Group•The Lancet•1998•PMID: 9742977
Key Finding: Landmark RCT: metformin reduced all-cause mortality by 36%, diabetes-related death by 42% over 10.7 years.
View on PubMedMetformin reduces all-cause mortality and diseases of ageing: systematic review
Campbell JM et al.•Ageing Res Rev•2017•PMID: 28802803
Key Finding: 53-study meta-analysis: metformin users had lower all-cause mortality than non-diabetics (HR=0.93).
View on PubMedMetformin as a Tool to Target Aging
Barzilai N et al.•Cell Metab•2016•PMID: 27304507
Key Finding: Outlines the TAME trial — first FDA-approved clinical trial testing a drug for aging as an indication.
View on PubMedCitations sourced from PubMed, Cochrane Library, and peer-reviewed journals. Study findings are summarized for accessibility. Always consult the original publication for full methodology and results.
📊 Evidence by Outcome
36% reduction in all-cause mortality (UKPDS 34); metformin users outlive non-diabetic controls by 15% (Bannister 2014). 53-study meta-analysis confirms geroprotective effects.
53 studies • Consistency: High • Effect: Large
42% reduction in diabetes-related death (UKPDS 34). HR=0.76 for CVD vs non-metformin therapies.
30 studies • Consistency: High • Effect: Large
31% reduction in cancer incidence and 34% in cancer mortality in pooled analysis of 47 studies. Effect attenuated to 10-18% after bias correction.
47 studies • Consistency: Moderate • Effect: Moderate
31% reduction in diabetes incidence in pre-diabetic populations (DPP, NEJM 2002). NNT=13.9 over 3 years.
10 studies • Consistency: High • Effect: Large
👥 Community Insights
500mg XR for 2 years. Fasting glucose from 98 to 82, HbA1c from 5.6 to 5.1. Zero side effects after first week.
Community member • USA• Verified
📋 Protocol Snapshot
Protocols are for informational purposes only. Always consult a qualified healthcare provider before starting any treatment protocol.
Where to Get It (UAE)
Browse all wellness centers →Related Treatments
Medical Disclaimer: The information on this page is for educational purposes only and is not intended as medical advice. Kamura Scores reflect a combination of research evidence, community data, and other factors — they are not clinical recommendations. Research citations are provided for reference; always consult the original publications for complete study details. Consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Individual results may vary.